Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)
Phase 3CompletedDevelopment Stage
Sedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic Polypectomy
Sedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic Polypectomy
Oct 1, 2013 → Mar 1, 2014
About Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS)
Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS) is a phase 3 stage product being developed by Johnson & Johnson for Sedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic Polypectomy. The current trial status is completed. This product is registered under clinical trial identifier NCT01961349. Target conditions include Sedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic Polypectomy.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01961349 | Phase 3 | Completed |
Competing Products
20 competing products in Sedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic Polypectomy